Relapsed/Refractory

The term “relapsed” refers to disease that reappears or grows again after a period of remission. The term “refractory” is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long.

Relapsed/refractory ALCL patients have many treatment options. For primary cutaneous ALCL the following treatments have been approved by the U.S. Food and Drug Administration (FDA):

• Brentuximab vedotin (Adcetris)

For systemic ALCL the following treatments have been approved by the U.S. Food and Drug Administration (FDA) :

• Romidepsin (Istodax)
• Belinostat (Beleodaq)
• Pralatrexate (Folotyn)
• Brentuximab vedotin (Adcetris)

Learn More

To learn more about ALCL, view the T-Cell Lymphomas Guide. Want to talk to someone? For answers to lymphoma-related questions 
and resources, contact our Lymphoma Resource Center at (800) 500-9976 or [email protected].